Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2022; 205:1449-1460..
COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study. ERJ Open Research. 2022; 8..
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal. 2022; 59..
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Annals of Neurology. 2022; 91:424-435..
Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. Journal of Pediatrics. 2022; 241:68-76.e3..
Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival. Pulmonary Circulation. 2022; 12..
Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine. 2021; 13..
Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. Journal of the American Heart Association. 2021; 10..
The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Research. 2021; 7..
Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study. Frontiers in Neurology. 2021; 12..
(2021) ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. 160:297-306..
NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021; 77:2040-2052..
Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Frontiers in Neurology. 2021; 12..
Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation: Genomic and Precision Medicine. 2021; 14..
United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2021; 159:311-327..
Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatric Research. 2020; 88:850-856..
Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Medicine. 2020; 18..
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine. 2020; 202:586-594..
Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics. 2020; 223:164-169.e1..
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype. Pulmonary Circulation. 2020; 10..
Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation. 2020; 141:1986-2000..
Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2020; 201:1407-1415..
Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest. 2020; 157:1606-1616..
Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension. European Respiratory Journal. 2020; 55..
Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal. 2020; 55..
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension. Nature Communications. 2019; 10..
Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension. Genome Medicine. 2019; 11..
Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. European Respiratory Journal. 2019; 54..
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary Circulation. 2019; 9..
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. The Lancet Respiratory Medicine. 2019; 7:227-238..
Genetics and genomics of pulmonary arterial hypertension. European Respiratory Journal. 2019; 53..
Hypoxia-induced Pulmonary Hypertension in Different Mouse Strains: Relation to Transcriptome. American Journal of Respiratory Cell and Molecular Biology. 2019; 60:106-116..
Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Medicine. 2018; 10..
Alpha galactosidase A activity in Parkinson's disease. Neurobiology of Disease. 2018; 112:85-90..
Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. Circulation: Genomic and Precision Medicine. 2018; 11..
2018; 37.. (497) The United States Pulmonary Hypertension Scientific Registry (USPHSR): Objectives and Preliminary Data. Journal of Heart Transplantation.